The global Doxorubicin Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.
Market Overview:
Global Doxorubicin Market is expected to reach USD 1.38 billion by 2024. Doxorubicin is an anticancer chemotherapy drug, a generic name for the trade name drug Rubex® and Adriamycin®. It is injected into a vein. It is an essential medicine on the World Health Organization's List, the safest and effective medicines needed in a health system. The Doxorubicin Market is estimated to grow at a significant CAGR of 6.4% over the forecast period as the scope and its applications are rising enormously across the globe.
Key Players:
- Pfizer
- Sun Pharmaceutical Industries Ltd.
- Cipla
- Cadila Pharmaceuticals
- SRS Pharmaceuticals PVT. LTD.
- Janssen Products, LP
Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/doxorubicin-market/request-sample
Growth Drivers:
Growing presence of cancer patients across the globe, increasing number of manufacturers in the market to control the shortage of drugs, and developed laboratories with the latest technological equipment’s for research are documented as the major driving factors for Doxorubicin Market. Also, inclusion of doxorubicin drug in several applications like neuroblastoma, AIDS-related Kaposi Sarcoma, and others may boost the overall market in the years to come.
However, side effects of drugs and high cost of treatment are the factors that may restrain overall market growth in the coming years. Doxorubicin Industry is segmented based on formulation, cancer type, distribution channel, and region. Doxorubicin injection and lyophilized doxorubicin powder are the formulations that could be explored in Doxorubicin in the forecast period.
Application Outlook:
- Ovarian cancer
- Multiple myeloma
- Kaposi Sarcoma
- Leukemia
- Bone sarcoma
- Breast cancer
- Endometrial cancer
- Gastric cancer
- Liver cancer
- Kidney cancer
- Other
Distribution Channel Outlook:
- E-Commerce
- Retail Pharmacies
- Hospitals Pharmacies
- Other
Regional Outlook:
Globally, North America accounted for the substantial market share of Doxorubicin in 2017 and is estimated to continue with its dominance in the near future. The reason behind the overall market growth could be presence of developed healthcare infrastructure, presence of key manufacturers in the region, and increasing number of cancer epidemiology. The United States is a major consumer of Doxorubicin in this region.
Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at the fastest pace in the foremost period. The aspects that may be ascribed to the growth comprise rising pharmaceutical market, developing healthcare infrastructure and growing occurrence of cancer mainly gastric cancer and lung cancer among population. The developing countries like India, Japan, and China are the major consumers of Doxorubicin in this region.
Browse Related Category Research Reports @ https://industryanalysisandnews.wordpress.com/
No comments:
Post a Comment